Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finch Therapeutics Group, Inc.

http://www.finchtherapeutics.com/

Latest From Finch Therapeutics Group, Inc.

Finance Watch: Restructurings, Layoffs Reflect Ongoing Uncertainty In Biotech

Sio Gene, Genocea, Solid Biosciences, Saniona and Black Diamond join First Wave, Zosano, Vallon, Finch, Magenta, ProQR and Imara on the growing list of biopharma firms reducing headcount to make their cash last until valuations return to a level that may support new fundraising. 

Financing Business Strategies

Hyloris Outlines Ambitious Growth Strategy During Full-Year Results

Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.

Sales & Earnings Strategy

Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures

Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.

Clinical Trials Vaccines

Summit's Lead Antimicrobial Fails Pivotal Study, May Spark Therapeutic Shift

Ridinilazole fell short of significance in a late-stage trial, with some analysts now anticipating the company will alter its therapeutic strategy entirely.

Clinical Trials Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Crestovo LLC
    • Finch Therapeutics Inc.
UsernamePublicRestriction

Register